ProPhase Labs (PRPH) Competitors

$0.10 -0.01 (-7.09%)

As of 01:04 PM Eastern

PRPH vs. ALBT, ORGS, SBFM, CANF, and QLGN

Should you buy ProPhase Labs stock or one of its competitors? MarketBeat compares ProPhase Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProPhase Labs include Avalon GloboCare (ALBT), Orgenesis (ORGS), Sunshine Biopharma (SBFM), Can-Fite BioPharma (CANF), and Qualigen Therapeutics (QLGN). These companies are all part of the "pharmaceutical products" industry.

How does ProPhase Labs compare to Avalon GloboCare?

Avalon GloboCare (NASDAQ:ALBT) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

1.4% of Avalon GloboCare shares are held by institutional investors. Comparatively, 9.4% of ProPhase Labs shares are held by institutional investors. 24.2% of Avalon GloboCare shares are held by insiders. Comparatively, 9.6% of ProPhase Labs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Avalon GloboCare has higher earnings, but lower revenue than ProPhase Labs. Avalon GloboCare is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalon GloboCare	$1.26M	1.92	-$18.26M	-$3.51	N/A
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.90	N/A

In the previous week, ProPhase Labs had 1 more articles in the media than Avalon GloboCare. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Avalon GloboCare. Avalon GloboCare's average media sentiment score of 0.00 equaled ProPhase Labs'average media sentiment score.

Company	Overall Sentiment
Avalon GloboCare	Neutral
ProPhase Labs	Neutral

Avalon GloboCare has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, ProPhase Labs has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market.

Avalon GloboCare has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Avalon GloboCare's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalon GloboCare	N/A	N/A	-74.36%
ProPhase Labs	-825.01%	-482.05%	-88.90%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalon GloboCare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Avalon GloboCare beats ProPhase Labs on 7 of the 12 factors compared between the two stocks.

How does ProPhase Labs compare to Orgenesis?

ProPhase Labs (NASDAQ:PRPH) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

ProPhase Labs has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.90	N/A
Orgenesis	$662K	3.51	-$55.36M	-$11.51	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, ProPhase Labs had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Orgenesis. ProPhase Labs' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
Orgenesis	Neutral

ProPhase Labs has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.06, indicating that its stock price is 206% more volatile than the broader market.

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ProPhase Labs has a net margin of -825.01% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Orgenesis	-3,827.81%	N/A	-130.18%

Summary

ProPhase Labs beats Orgenesis on 9 of the 13 factors compared between the two stocks.

How does ProPhase Labs compare to Sunshine Biopharma?

ProPhase Labs (NASDAQ:PRPH) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Sunshine Biopharma had 22 more articles in the media than ProPhase Labs. MarketBeat recorded 23 mentions for Sunshine Biopharma and 1 mentions for ProPhase Labs. ProPhase Labs' average media sentiment score of 0.00 beat Sunshine Biopharma's score of -0.10 indicating that ProPhase Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProPhase Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sunshine Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	21 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Comparatively, 0.0% of Sunshine Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Sunshine Biopharma has a net margin of -18.45% compared to ProPhase Labs' net margin of -825.01%. Sunshine Biopharma's return on equity of -27.75% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Sunshine Biopharma	-18.45%	-27.75%	-21.57%

ProPhase Labs has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market. Comparatively, Sunshine Biopharma has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Sunshine Biopharma has a consensus price target of $7.00, suggesting a potential upside of 1,490.91%. Given Sunshine Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sunshine Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sunshine Biopharma has higher revenue and earnings than ProPhase Labs. Sunshine Biopharma is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.90	N/A
Sunshine Biopharma	$36.31M	0.06	-$5.97M	-$1.29	N/A

Summary

Sunshine Biopharma beats ProPhase Labs on 12 of the 16 factors compared between the two stocks.

How does ProPhase Labs compare to Can-Fite BioPharma?

ProPhase Labs (NASDAQ:PRPH) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

ProPhase Labs has a beta of 0.15, suggesting that its share price is 85% less volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.09, suggesting that its share price is 9% more volatile than the broader market.

Can-Fite BioPharma has lower revenue, but higher earnings than ProPhase Labs. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.90	N/A
Can-Fite BioPharma	$405K	5.26	-$7.63M	-$35.80	N/A

Can-Fite BioPharma has a consensus price target of $42.50, indicating a potential upside of 1,207.69%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than ProPhase Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Can-Fite BioPharma had 7 more articles in the media than ProPhase Labs. MarketBeat recorded 8 mentions for Can-Fite BioPharma and 1 mentions for ProPhase Labs. Can-Fite BioPharma's average media sentiment score of 0.90 beat ProPhase Labs' score of 0.00 indicating that Can-Fite BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProPhase Labs	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Can-Fite BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Can-Fite BioPharma has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Can-Fite BioPharma's return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Can-Fite BioPharma	N/A	N/A	N/A

Summary

Can-Fite BioPharma beats ProPhase Labs on 12 of the 16 factors compared between the two stocks.

How does ProPhase Labs compare to Qualigen Therapeutics?

ProPhase Labs (NASDAQ:PRPH) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment and earnings.

Qualigen Therapeutics has lower revenue, but higher earnings than ProPhase Labs. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.12	-$53.36M	-$3.90	N/A
Qualigen Therapeutics	N/A	N/A	-$6.26M	-$7.50	N/A

Qualigen Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -825.01%. Qualigen Therapeutics' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Qualigen Therapeutics	N/A	N/A	-202.16%

ProPhase Labs has a beta of 0.15, suggesting that its share price is 85% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Qualigen Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, ProPhase Labs had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 1 mentions for ProPhase Labs and 0 mentions for Qualigen Therapeutics. ProPhase Labs' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
Qualigen Therapeutics	Neutral

Summary

ProPhase Labs beats Qualigen Therapeutics on 7 of the 11 factors compared between the two stocks.

Get ProPhase Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRPH vs. The Competition

Export

Metric	ProPhase Labs	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$615K	$2.99B	$6.25B	$12.23B
Dividend Yield	N/A	1.96%	2.80%	5.27%
P/E Ratio	-0.03	17.04	20.79	25.04
Price / Sales	0.12	251.21	531.21	72.18
Price / Cash	N/A	57.15	43.09	54.25
Price / Book	0.04	4.39	9.81	6.83
Net Income	-$53.36M	$74.99M	$3.55B	$335.69M
7 Day Performance	-14.83%	-4.89%	-2.07%	-2.03%
1 Month Performance	N/A	-8.30%	-3.90%	-1.90%
1 Year Performance	-96.81%	28.66%	29.39%	27.36%

ProPhase Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRPH ProPhase Labs	0.0745 of 5 stars	$0.10 -7.1%	N/A	-97.2%	$615K	$5.06M	N/A	130	Upcoming Earnings
ALBT Avalon GloboCare	0.3223 of 5 stars	$0.29 -9.3%	N/A	-91.4%	$2.42M	N/A	N/A	5	Gap Up
ORGS Orgenesis	N/A	$0.45 +863.6%	N/A	-97.7%	$2.33M	$662K	N/A	150	Gap Up
SBFM Sunshine Biopharma	2.8004 of 5 stars	$0.44 -13.7%	$7.00 +1,490.9%	-66.0%	$2.20M	$36.31M	N/A	3	Trending News Earnings Report Gap Down High Trading Volume
CANF Can-Fite BioPharma	2.8372 of 5 stars	$3.25 -0.3%	$42.50 +1,207.7%	-84.5%	$2.13M	$405K	N/A	8	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRPH) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProPhase Labs (PRPH) Competitors

PRPH vs. ALBT, ORGS, SBFM, CANF, and QLGN

How does ProPhase Labs compare to Avalon GloboCare?

Summary

How does ProPhase Labs compare to Orgenesis?

Summary

How does ProPhase Labs compare to Sunshine Biopharma?

Summary

How does ProPhase Labs compare to Can-Fite BioPharma?

Summary

How does ProPhase Labs compare to Qualigen Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProPhase Labs (PRPH) Competitors

PRPH vs. ALBT, ORGS, SBFM, CANF, and QLGN

How does ProPhase Labs compare to Avalon GloboCare?

Do insiders and institutionals have more ownership in ALBT or PRPH?

Which has stronger earnings & valuation, ALBT or PRPH?

Does the media favor ALBT or PRPH?

Which has more volatility & risk, ALBT or PRPH?

Is ALBT or PRPH more profitable?

Do analysts prefer ALBT or PRPH?

Summary

How does ProPhase Labs compare to Orgenesis?

Which has stronger earnings and valuation, PRPH or ORGS?

Do analysts prefer PRPH or ORGS?

Does the media prefer PRPH or ORGS?

Which has more risk and volatility, PRPH or ORGS?

Do insiders and institutionals hold more shares of PRPH or ORGS?

Is PRPH or ORGS more profitable?

Summary

How does ProPhase Labs compare to Sunshine Biopharma?

Does the media prefer PRPH or SBFM?

Do institutionals & insiders hold more shares of PRPH or SBFM?

Is PRPH or SBFM more profitable?

Which has more volatility and risk, PRPH or SBFM?

Do analysts prefer PRPH or SBFM?

Which has better valuation and earnings, PRPH or SBFM?

Summary

How does ProPhase Labs compare to Can-Fite BioPharma?

Which has more risk & volatility, PRPH or CANF?

Which has higher earnings and valuation, PRPH or CANF?

Do analysts prefer PRPH or CANF?

Does the media favor PRPH or CANF?

Do insiders & institutionals have more ownership in PRPH or CANF?

Is PRPH or CANF more profitable?

Summary

How does ProPhase Labs compare to Qualigen Therapeutics?

Which has preferable valuation and earnings, PRPH or QLGN?

Is PRPH or QLGN more profitable?

Which has more volatility & risk, PRPH or QLGN?

Do institutionals and insiders have more ownership in PRPH or QLGN?

Do analysts prefer PRPH or QLGN?

Does the media favor PRPH or QLGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRPH vs. The Competition

ProPhase Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools